KLRK1 and plasma cell myeloma: Alessandra and colleagues showed that myeloma cells treated with therapeutic agents such as melphalan up-regulated the expression of DNAX accessory molecule-1 and natural killer group 2D (NKG2D) ligands and exhibited a senescent-like phenotype [39].